Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Jakavi

Harnessing social media for campaign success

Digital excellence from Ruder Finn's meningitis work for Novartis

Novartis building

Novartis signs cell therapy deal with Regenerex

Involves platform that could allow transplant patients to live without lifelong immunosuppression

- PMLiVE

Otsuka to buy cancer biopharma Astex

Takes control of company behind Dacogen in $886m deal

- PMLiVE

Bayer wins new Eylea approval in Europe

Macular oedema indication will provide more competition for Novartis’ Lucentis

- PMLiVE

AZ’s olaparib enters phase III for ovarian cancer

Development of the drug had previously been halted in 2011

Novartis building

Novartis wins childhood arthritis indication for Ilaris in EU

EC gives green light to drug for the treatment of systemic juvenile idiopathic arthritis

- PMLiVE

GSK melanoma therapy Tafinlar cleared in EU

Follows approvals for skin cancer drug in US, Canada and Australia

Novartis day

More data backs Novartis’ serelaxin in heart failure

European Society of Cardiology (ESC) meeting told of significant additional benefits

Roche - Basel

Roche wins EU approval for injectable Herceptin

Can reduce cancer drug's administration time from 90 minutes to two minutes

- PMLiVE

FDA investigates safety of Novartis’ MS drug

Agency to determine association between Gilenya and rare brain infection

Bayer symbol

EU nod for Bayer’s Stivarga as Nexavar gets US priority review

Advances pharma company’s ambitions in cancer

Novartis building

NICE backs Novartis’ Jetrea in rare eye condition

Recommends drug be available for NHS use to treat vitreomacular traction

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links